A study to test different doses of BI 1831169 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors).
- Conditions
- solid tumors
- Registration Number
- 2024-512504-19-00
- Lead Sponsor
- Boehringer Ingelheim International GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing, recruiting
- Sex
- Not specified
- Target Recruitment
- 97
Not provided
Not provided
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (21)
Fundacion Instituto Valenciano De Oncologia
🇪🇸Valencia, Spain
Hospital Universitario Fundacion Jimenez Diaz
🇪🇸Madrid, Spain
Institut Catala D'oncologia
🇪🇸L'hospitalet De Llobregat, Spain
Clinica Universidad De Navarra
🇪🇸Pamplona, Spain
Hospital Quironsalud Barcelona
🇪🇸Barcelona, Spain
Universitaetsklinikum Heidelberg AöR
🇩🇪Heidelberg, Germany
Charite Universitaetsmedizin Berlin KöR
🇩🇪Berlin, Germany
Universitaetsklinikum Tuebingen AöR
🇩🇪Tuebingen, Germany
Universitaetsklinikum Ulm AöR
🇩🇪Ulm, Germany
Institut Gustave Roussy
🇫🇷Villejuif, France
Scroll for more (11 remaining)Fundacion Instituto Valenciano De Oncologia🇪🇸Valencia, SpainDavid LorenteSite contact34961104065dlorente@fivo.org